Disease · MONDO_0005300
Comparisons in its trials266
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 266
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| SGLT-2i (Incl. Empa) (Matched to DPP-4i) vs DPP-4i (Matched to SGLT-2i): deaths from any cause | 1,371 of 163,812 | 2,524 of 163,812 | 327,624 | NCT03817463 | Trial comparisons |
| Empagliflozin 10 mg vs Placebo: deaths from any cause | 314 of 3,304 | 353 of 3,305 | 6,609 | NCT03594110 | Trial comparisons |
| Empagliflozin 10 mg vs Placebo: serious adverse events | 1,089 of 3,304 | 1,167 of 3,305 | 6,609 | NCT03594110 | Trial comparisons |
| Intent-to-Treat (ITT) Atrasentan vs Intent-to-Treat Placebo: Time to First Occurrence of a Component of Composite Renal Endpoint for All Randomized Participants (Pooled) | 152 of 1,834 | 192 of 1,834 | 3,668 | NCT01858532 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 276 of 1,768 | 290 of 1,769 | 3,537 | NCT02892149 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 973 of 1,768 | 1,032 of 1,769 | 3,537 | NCT02892149 | Trial comparisons |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: deaths from any cause | 557 of 1,409 | 558 of 1,409 | 2,818 | NCT00773513 | Trial comparisons |
| Erythropoiesis Stimulating Agents vs Methoxy Polyethylene Glycol-Epoetin Beta: serious adverse events | 1,123 of 1,409 | 1,097 of 1,409 | 2,818 | NCT00773513 | Trial comparisons |
| Roxadustat vs Placebo: deaths from any cause | 284 of 1,384 | 245 of 1,377 | 2,761 | NCT02174627 | Trial comparisons |
| Roxadustat vs Placebo: serious adverse events | 795 of 1,384 | 749 of 1,377 | 2,761 | NCT02174627 | Trial comparisons |
Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the First Occurrence of a Component of the Composite Renal Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 79 of 1,325 | 105 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to a 50% Estimated Glomerular Filtration Rate Reduction in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 78 of 1,325 | 88 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to Cardio-renal Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 147 of 1,325 | 172 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
| Intent-to-Treat (ITT) Responder Atrasentan vs Intent-to-Treat (ITT) Responder Placebo: Time to the Cardiovascular Composite Endpoint in the Intent-to-Treat (ITT) Responder Set (as Randomized) | 72 of 1,325 | 81 of 1,323 | 2,648 | NCT01858532 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 180 of 878 | 168 of 870 | 1,748 | NCT02648347 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 573 of 878 | 561 of 870 | 1,748 | NCT02648347 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: deaths from any cause | 139 of 861 | 139 of 862 | 1,723 | NCT02680574 | Trial comparisons |
| Vadadustat vs Darbepoetin Alfa: serious adverse events | 504 of 861 | 488 of 862 | 1,723 | NCT02680574 | Trial comparisons |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8 | 259 of 1,027 | 121 of 510 | 1,537 | NCT02940860 | Trial comparisons |
| Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8 | 307 of 1,027 | 133 of 510 | 1,537 | NCT02940860 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005300/comparisons